Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-19
    E.g., 2018-11-19

Articles

Pages

79713 items
11:45 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Other News

Gyroscope-led consortium gets UK funding for cost-effective manufacture of AAV gene therapies

A consortium led by retinal gene therapy company Gyroscope Therapeutics Ltd. (Stevenage, U.K.) received a two-year, £1.1 million ($1.4 million) award from Innovate UK to develop a manufacturing platform for production of adeno-associated virus (AAV)...
11:13 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Sobi springboards U.S. growth in deal for AZ's Synagis

Swedish Orphan Biovitrum AB (SSE:SOBI) obtained U.S. rights to commercialize infectious disease drug Synagis palivizumab from AstraZeneca plc (LSE:AZN; NYSE:AZN) for $1.5 billion up front. Sobi called the deal, which also includes profit sharing with...
10:57 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Other News

DeepMind's healthcare team joins Google

The DeepMind Technologies subsidiary of Alphabet Inc. (NASDAQ:GOOG) is merging its health team into Google Inc. following Google's announcement that David Feinberg will be joining the tech company to organize its healthcare efforts. Feinberg is...
10:56 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

ICER: asthma mAbs should be 50% cheaper for cost effectiveness

The Institute for Clinical and Economic Review (ICER) said the costs of five asthma mAbs would need to decrease by at least 50% to be cost effective in a final evidence report. ICER said that the...
10:50 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Other News

Google Brings Geisinger CEO on Board to Focus on Healthcare

Beyond a quick mention of Verily Life Sciences LLC and AI, Google Inc. is saying little about what it plans to do with its healthcare initiatives now that David Feinberg is leaving Geisinger Health System...
10:01 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Oxford BioDynamics partners EpiSwitch platform

Oxford BioDynamics plc (LSE:OBD) said it partnered with an undisclosed major U.S. pharma to use its EpiSwitch epigenetic biomarker platform to develop predictive biomarkers for immuno-oncology therapeutics. The company did not respond to inquiries. Oxford BioDynamics...
10:00 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

SVB acquiring Leerink amid record year for IPOs

With IPOs continuing at a torrid pace, SVB Financial Group (NASDAQ:SIVB), the parent company of high-tech commercial lender Silicon Valley Bank, announced on Oct. 13 that it will acquire Leerink Partners for $280 million. Leerink, a...
9:55 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Daiichi, GSK to dissolve vaccines JV

Daiichi Sankyo Co. Ltd. (Tokyo:4568) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) agreed to dissolve their JV, Japan Vaccine Co. Ltd. In a statement, Daiichi said, “in consideration of changes in the Japan Vaccine business situation, both...
9:44 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

AbbVie strengthens early stage neurology focus with Mission deal

Mission Therapeutics Ltd. (Cambridge, U.K.) and AbbVie Inc. (NYSE:ABBV) partnered to develop deubiquitinase inhibitors for Alzheimer's and Parkinson's diseases. The deal is the second in as many weeks for AbbVie for early stage neurology candidates. Deubiquitinases,...
9:40 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Helperby, UCLA to explore antibiotic combos

Helperby Therapeutics Ltd. (London, U.K.) partnered with University of California Los Angeles (Los Angeles, Calif.) to develop undisclosed combinations of antibiotics. The partners will target antimicrobial resistant bacteria and under the deal will share data and...

Pages